Ajovy is a biologic drug used to prevent migraine headaches [1]. It is administered via injection and works by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a role in migraine development [1][2].
How does Ajovy work for migraine prevention?
Ajovy's mechanism of action involves binding to the CGRP ligand, preventing it from attaching to its receptor [1][3]. CGRP is a neuropeptide that is elevated during migraine attacks and is believed to contribute to vasodilation and inflammation in the brain, processes implicated in migraine pain [2]. By blocking CGRP, Ajovy reduces these effects, thereby preventing migraine [1].
What is Ajovy approved for?
Ajovy (fremanezumab-vfrm) is approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of episodic migraine and chronic migraine in adults [1].
Who makes Ajovy?
Teva Pharmaceuticals manufactures and markets Ajovy [1].
When does Ajovy's patent expire?
Patent exclusivity for Ajovy is a complex landscape influenced by multiple patents covering various aspects of the drug, including its composition, manufacturing, and method of use [4]. Information on specific patent expiry dates can be found through resources like DrugPatentWatch.com [4]. The general timeframe for biologic exclusivity is typically 12 years in the U.S., but this can be extended by various factors including pediatric exclusivity and orphan drug exclusivity, though these may not apply to Ajovy [5].
Can biosimilars of Ajovy be made?
Biosimilars are biological products highly similar to an already approved biologic. The development and approval of Ajovy biosimilars would depend on the expiration of relevant patents and regulatory pathways established for biosimilar approval [5]. Challenges can arise in demonstrating biosimilarity for complex biologics [5].
What are the alternatives to Ajovy for migraine prevention?
Several other treatment options exist for migraine prevention, including other CGRP-targeting therapies (both injectable monoclonal antibodies like Aimovig and Emgality, and oral gepants), as well as older preventive medications such as beta-blockers, antidepressants, and anticonvulsants [2][6]. The choice of treatment often depends on individual patient factors, including migraine type, frequency, severity, comorbidities, and response to previous therapies [6].
What are the potential side effects of Ajovy?
Common side effects associated with Ajovy treatment include injection site reactions (pain, redness, itching) and upper respiratory tract infections [1]. Less common but serious side effects can include hypersensitivity reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider.